Skip to main content
Top
Published in: Calcified Tissue International 4/2017

01-10-2017 | Original Research

Muscle Function in Osteogenesis Imperfecta Type IV

Authors: Louis-Nicolas Veilleux, Vasiliki B. Darsaklis, Kathleen Montpetit, Francis H. Glorieux, Frank Rauch

Published in: Calcified Tissue International | Issue 4/2017

Login to get access

Abstract

Results of previous studies suggest that children and adolescents with osteogenesis imperfecta (OI) type IV have muscle force deficits. However, muscle function remains to be objectively quantified in this population. This study aimed to assess upper and lower extremity muscle function in patients with OI type IV. It was carried out in the outpatient department of a pediatric orthopedic hospital; 27 individuals with OI type IV (7–21 years; 13 males), 27 age- and sex-matched individuals with OI type I, and 27 age- and sex-matched controls. Upper extremity muscle force was assessed with hydraulic hand dynamometry, and lower extremity muscle function (peak force per body weight and peak power per body mass) was measured by mechanography through five tests: multiple two-legged hopping, multiple one-legged hopping, single two-legged jump, chair-rise test, and heel-rise test. Upper-limb grip force was normal for patients with OI type IV when compared to height and sex reference data (average z-score = 0.17 ± 1.30; P = 0.88). Compared to age- and sex-matched controls, patients with OI type IV had approximately 30% lower-limb peak force and 50% peak power deficits (P values <0.05). At the lower-limb level, they had a 50% lower peak power than age- and sex-matched patients with OI type I (P < 0.05). Patients with OI type IV have normal upper-limb muscle force but a muscle function deficit at the lower-limb level. These results suggest that lower-limb muscle weakness may contribute to functional deficits in these individuals.
Literature
3.
go back to reference Veilleux LN, Lemay M, Pouliot-Laforte A, Cheung MS, Glorieux FH, Rauch F (2014) Muscle anatomy and dynamic muscle function in osteogenesis imperfecta type I. J Clin Endocrinol Metab 99:E356–E362. doi:10.1210/jc.2013-3209 CrossRefPubMed Veilleux LN, Lemay M, Pouliot-Laforte A, Cheung MS, Glorieux FH, Rauch F (2014) Muscle anatomy and dynamic muscle function in osteogenesis imperfecta type I. J Clin Endocrinol Metab 99:E356–E362. doi:10.​1210/​jc.​2013-3209 CrossRefPubMed
5.
go back to reference Graf A, Hassani S, Krzak J, Caudill A, Flanagan A, Bajorunaite R et al (2009) Gait characteristics and functional assessment of children with type I osteogenesis imperfecta. J Orthop Res 27:1182–1190. doi:10.1002/jor.20871 CrossRefPubMed Graf A, Hassani S, Krzak J, Caudill A, Flanagan A, Bajorunaite R et al (2009) Gait characteristics and functional assessment of children with type I osteogenesis imperfecta. J Orthop Res 27:1182–1190. doi:10.​1002/​jor.​20871 CrossRefPubMed
13.
go back to reference Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L et al (2002) Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 31:12–18CrossRefPubMed Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L et al (2002) Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 31:12–18CrossRefPubMed
14.
go back to reference Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R et al (2002) Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45–60CrossRefPubMed Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R et al (2002) Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45–60CrossRefPubMed
15.
16.
go back to reference Feldman AB, Haley SM, Coryell J (1990) Concurrent and construct validity of the pediatric evaluation of disability inventory. Phys Ther 70:602–610CrossRefPubMed Feldman AB, Haley SM, Coryell J (1990) Concurrent and construct validity of the pediatric evaluation of disability inventory. Phys Ther 70:602–610CrossRefPubMed
17.
go back to reference Bleck EE (1981) Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop Relat Res. 159:111–122 Bleck EE (1981) Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop Relat Res. 159:111–122
18.
go back to reference Veilleux LN, Rauch F (2010) Reproducibility of jumping mechanography in healthy children and adults. J Musculoskelet Neuronal Interact 10:256–266PubMed Veilleux LN, Rauch F (2010) Reproducibility of jumping mechanography in healthy children and adults. J Musculoskelet Neuronal Interact 10:256–266PubMed
20.
go back to reference Foldvari M, Clark M, Laviolette LC, Bernstein MA, Kaliton D, Castaneda C et al (2000) Association of muscle power with functional status in community-dwelling elderly women. J Gerontol A Biol Sci Med Sci 55:M192–M199CrossRefPubMed Foldvari M, Clark M, Laviolette LC, Bernstein MA, Kaliton D, Castaneda C et al (2000) Association of muscle power with functional status in community-dwelling elderly women. J Gerontol A Biol Sci Med Sci 55:M192–M199CrossRefPubMed
21.
go back to reference Mathiowetz V, Wiemer DM, Federman SM (1986) Grip and pinch strength: norms for 6- to 19-year-olds. Am J Occup Ther 40:705–711CrossRefPubMed Mathiowetz V, Wiemer DM, Federman SM (1986) Grip and pinch strength: norms for 6- to 19-year-olds. Am J Occup Ther 40:705–711CrossRefPubMed
22.
go back to reference Sumnik Z, Matyskova J, Hlavka Z, Durdilova L, Soucek O, Zemkova D (2013) Reference data for jumping mechanography in healthy children and adolescents aged 6–18 years. J Musculoskelet Neuronal Interact 13:297–311PubMed Sumnik Z, Matyskova J, Hlavka Z, Durdilova L, Soucek O, Zemkova D (2013) Reference data for jumping mechanography in healthy children and adolescents aged 6–18 years. J Musculoskelet Neuronal Interact 13:297–311PubMed
26.
go back to reference Sims TJ, Miles CA, Bailey AJ, Camacho NP (2003) Properties of collagen in OIM mouse tissues. Connect Tissue Res 44(Suppl 1):202–205CrossRefPubMed Sims TJ, Miles CA, Bailey AJ, Camacho NP (2003) Properties of collagen in OIM mouse tissues. Connect Tissue Res 44(Suppl 1):202–205CrossRefPubMed
28.
go back to reference Huijing PA (1999) Muscle as a collagen fiber reinforced composite: a review of force transmission in muscle and whole limb. J Biomech 32:329–345CrossRefPubMed Huijing PA (1999) Muscle as a collagen fiber reinforced composite: a review of force transmission in muscle and whole limb. J Biomech 32:329–345CrossRefPubMed
29.
30.
go back to reference Matheson LA, Duffy S, Maroof A, Gibbons R, Duffy C, Roth J (2013) Intra- and inter-rater reliability of jumping mechanography muscle function assessments. J Musculoskelet Neuronal Interact 13:480–486PubMed Matheson LA, Duffy S, Maroof A, Gibbons R, Duffy C, Roth J (2013) Intra- and inter-rater reliability of jumping mechanography muscle function assessments. J Musculoskelet Neuronal Interact 13:480–486PubMed
Metadata
Title
Muscle Function in Osteogenesis Imperfecta Type IV
Authors
Louis-Nicolas Veilleux
Vasiliki B. Darsaklis
Kathleen Montpetit
Francis H. Glorieux
Frank Rauch
Publication date
01-10-2017
Publisher
Springer US
Published in
Calcified Tissue International / Issue 4/2017
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-017-0287-y

Other articles of this Issue 4/2017

Calcified Tissue International 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine